Company intelligence / Profile preview

Genomenon

Ann Arbor, Michigan, United Statesgenomenon.com ↗

Ownership: Private
Development stage: Other

Overview

Genomenon's platforms provide curated genomic evidence to accelerate variant interpretation in rare disease and oncology. Their databases cover over 27 million variants and thousands of gene-disease relationships. The company partners with pharma, clinical labs, and academic centers to improve diagnosis rates and support precision medicine development. No clinical trial results as they are not a drug developer.

Therapeutic areas: Rare DiseasesOncologyOther
Industry: Molecular Diagnostics

Partnerships

Mirum Pharmaceuticals (rare disease variant landscape project)GenomOncology (data integration partnership)

Beyond the preview

Go deeper on Genomenon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genomenon.

Explore the full profile